Jasper Therapeutics - Class A (JSPR) closed at $0.52 on October 30, 2026, down 2.2% from the previous close, on volume of 382,253 shares (30-day average 389,464).
Data as of October 30, 2026.
Globe Newswire (Thu, 15-Oct 8:00 AM ET)
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
Globe Newswire (Wed, 7-Oct 8:00 AM ET)
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Globe Newswire (Tue, 15-Sep 4:05 PM ET)
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Wed, 9-Sep 8:00 AM ET)
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Fri, 14-Aug 11:00 AM ET)
Market Chameleon (Tue, 2-Dec 4:54 AM ET)
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Jasper Therapeutics - Class A trades on the NASDAQ stock market under the symbol JSPR.
As of November 2, 2026, JSPR stock price was flat at $0.52 with 161,355 million shares trading.
JSPR has a beta of 3.20, meaning it tends to be more sensitive to market movements. JSPR has a correlation of 0.11 to the broad based SPY ETF.
JSPR has a market cap of $17.30 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, JSPR traded as high as $31.01 and as low as $.32.
The top ETF exchange traded funds that JSPR belongs to (by Net Assets): VTI, VXF.
JSPR has underperformed the market in the last year with a return of -76.1%, while the SPY ETF gained +12.2%. In the last 3 month period, JSPR fell short of the market, returning -16.2%, while SPY returned +2.0%. However, in the most recent 2 weeks JSPR has outperformed the stock market by returning +8.4%, while SPY returned -1.1%.
JSPR support price is $.49 and resistance is $.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JSPR shares will trade within this expected range on the day.
